Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial

Published:2021-11 Issue:11 Volume:9 Page:1299-1312
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Diver Sarah,Khalfaoui Latifa,Emson Claire,Wenzel Sally E,Menzies-Gow Andrew,Wechsler Michael E,Johnston James,Molfino Nestor,Parnes Jane R,Megally Ayman,Colice Gene,Brightling Christopher E

Funder

AstraZeneca plc

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Type 2 inflammation in asthma—present in most, absent in many;Fahy;Nat Rev Immunol,2015

2. Lung damage and airway remodelling in severe asthma;Brightling;Clin Exp Allergy,2012

3. Airway remodeling in asthma;Hough;Front Med (Lausanne),2020

4. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma;Djukanović;Am Rev Respir Dis,1992

5. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial;Busse;Lancet Respir Med,2019

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choosing the right biologic treatment for individual patients with severe asthma – Lessons learnt from Picasso;Respiratory Medicine;2024-11

2. New Therapies in Outpatient Pulmonary Medicine;Medical Clinics of North America;2024-09

3. Differences in the direct effects of various type 2 cytokines on functions of blood eosinophils from healthy subjects;Asia Pacific Allergy;2024-08-19

4. Eosinophils and T2 inflammation in severe asthma;Exploration of Asthma & Allergy;2024-08-13

5. IL-33 released during challenge phase regulates allergic asthma in an age-dependent way;Cellular & Molecular Immunology;2024-08-12